# FDA Approves Keytruda Plus Trodelvy as First-Line Treatment for PD-L1+ TNBC

> fda · REPORTED · 2026-06-22

The FDA approved Merck's Keytruda in combination with Trodelvy as a first-line treatment for patients with PD-L1-positive advanced triple-negative breast cancer, based on Phase 3 data showing meaningful improvements in progression-free survival versus standard care. The decision broadens treatment options in an indication with historically limited frontline therapies.

- Company: Merck
- Sector: oncology
- Primary source: https://realeconomy.rsmus.com/5-things-to-know-in-life-sciences-week-of-june-22-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.